Inactive Instrument

ORCHAR Nasdaq

US68570P1012

ORCHAR : Orchard Therapeutics to Webcast Conference Call of First Quarter 2020 Financial Results

May 04, 2020 at 05:13 am EDT

BOSTON - Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to report its first quarter 2020 financial results and other business updates.

A live webcast will be available under 'News & Events' in the Investors & Media section of the company's website at orchard-tx.com. The conference call can be accessed by dialing (866) 987-6504 (U.S. domestic) or +1 (602) 563-8620 (international) and referring to conference ID 8348144. A replay of the webcast will be archived on the Orchard website following the presentation.

About Orchard

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically-modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. The company has one of the deepest gene therapy product candidate pipelines in the industry and is advancing seven clinical-stage programs across multiple therapeutic areas, including inherited neurometabolic disorders, primary immune deficiencies and blood disorders, where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Contact:

Renee Leck

Tel: +1 862-242-0764

Email: Renee.Leck@orchard-tx.com

Latest news about ORCHAR

Orchard Therapeutics Receives FDA Approval of Lenmeldy? (atidarsagene autotemcel)	Mar. 18	CI
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome	Feb. 05	CI
Japanese Shares Skid as Inflation Slows Faster-than-Expected in January	Jan. 26	MT
Kyowa Kirin Acquires All Outstanding Shares of Orchard Therapeutics	Jan. 25	MT
Orchard Therapeutics plc Announces Board Changes	Jan. 24	CI
Orchard Therapeutics Completes Sale to Japan's Kyowa Kirin	Jan. 24	MT
Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index	Jan. 24	CI
Kyowa Kirin Co., Ltd. completed the acquisition of Orchard Therapeutics plc from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.	Jan. 23	CI
Orchard Therapeutics’ Gene Therapy Gets Swiss Regulatory Approval	Dec. 11	MT
Orchard Therapeutics Receives Swiss Agency for Therapeutic Products Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy	Dec. 11	CI
Orchard Therapeutics Gets FDA Fast Track Designation for Enzyme Deficiency Treatment	Nov. 30	MT
Orchard Therapeutics plc Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH	Nov. 30	CI
Earnings Flash (ORTX) ORCHARD THERAPEUTICS (EUROPE) LIMITED Posts Q3 Revenue $6.3M	Nov. 13	MT
Orchard Therapeutics plc Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 13	CI
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-Of-Concept Study of Otl-203 in Mps-Ih At Esgct 2023	23-10-26	CI
Japanese Shares Close Lower on Losses by Electronics, Energy Stocks; Kyowa Kirin Adds 1%	23-10-06	MT
Kyowa Kirin to Wholly Acquire Outstanding Shares of Orchard Therapeutics	23-10-06	MT
ADRs End Higher; Orchard Therapeutics PLC Climbs 96%	23-10-05	DJ
US Equity Markets Close Down Thursday as Jobless Claims Rise Less Than Forecast	23-10-05	MT
Sector Update: Health Care Stocks Advancing Late Afternoon	23-10-05	MT
Top Midday Gainers	23-10-05	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	23-10-05	MT
Sector Update: Health Care	23-10-05	MT
Cantor Fitzgerald Downgrades Orchard Therapeutics to Neutral From Overweight, Raises Price Target to $16 From $15	23-10-05	MT
FTSE 100 Closed Up 0.5% Despite Oil Price Drag	23-10-05	DJ

Chart ORCHAR

Duration

Period

More charts

Company Profile

Orchard Therapeutics plc is a gene therapy company. The Company is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient's autologous HSCs into a gene-modified cellular drug product to treat the patient's disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.79%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.57%	354B
MERCK & CO., INC.	+20.52%	331B
ABBVIE INC.	+3.09%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-5.85%	144B

Other Pharmaceuticals